Breadcrumb

LCBG Trainee Presenters Awarded at the 2023 CCR-FYI Colloquium

Image
Photo of LCBG trainees at the 2023 CCR-FYI Colloquium
LCBG trainees at the CCR-FYI Colloquium on May 4, 2023. Back row: Victoria Gonzalez, Hualong Yan, Young Im Kim, Shasha Wang, Payel Mondal, Liddy McCulla, Isabella Church, Rand Buenaventura, Christine Carney, Zachary Millman. Front row: Tamara McErlain, Chloe (Wang-Ning) Li, Lauren Ziemer, Gamze Ayaz Sen, Puneet Mann, GeGe Clements, Morgan Glass, Snehal Gaikwad.

The CCR Fellows and Young Investigators (FYI) Colloquium was held on May 4-5, 2023 at the NCI Shady Grove campus in Rockville, MD. This annual two-day event offers keynote addresses from extramural and intramural speakers along with panels and workshops to highlight the career development of CCR fellows. The Colloquium was widely attended by trainees from the LCBG, several of which were selected to give oral presentations.

Oral presentations by LCBG trainees

Hualong Yan, Ph.D., postdoctoral fellow, Huang Lab
“Targeting interacting partners of ZMIZ1, a super-enhancer binding pioneer transcriptional coactivator, is a novel therapeutical approach to treat osteosarcoma.”

Young-Im Kim, Ph.D., postdoctoral fellow, Huang Lab
“The role of GPC1 in regulating immune environment of osteosarcoma.”

Natalia Garcia Dutton, B.S., postbaccalaureate fellow, Mock Lab
“Identification of a mEAK-7 small molecule inhibitor for use in cancer therapies.”

Colloquium awards recognizing LCBG trainees

Several LCBG trainees were recognized with awards for their oral or poster presentations.

Outstanding Oral Presentation

Hualong Yan, Ph.D., postdoctoral fellow, Huang Lab
“Targeting interacting partners of ZMIZ1, a super-enhancer binding pioneer transcriptional coactivator, is a novel therapeutical approach to treat osteosarcoma.”

Outstanding Poster Presentation

Tamara McErlain, M.S., graduate student, Murgai Lab
“Pericyte directed metabolic reprogramming of the pre-metastatic microenvironment.”

John Han, B.S., MRSP fellow, Luo Lab
“A non-conserved histidine residue on KRAS drives paralog selectivity of the KRAS G12D inhibitor MRTX1133."